Edwards Lifesciences (EW) EBITDA Margin (2009 - 2026)

Edwards Lifesciences has reported EBITDA Margin for 18 years, with the latest figure at 29.48% in Q2 2026.

• On a quarterly basis, EBITDA Margin rose 264.0% year-over-year to 29.48% in Q2 2026; TTM through Jun 2026 was 22.25%, a 359.0% decrease from a year earlier, with the FY2025 full-year figure at 20.84%, down 451.0% from the prior year.
• EBITDA Margin was 29.48% for Q2 2026 at Edwards Lifesciences, up from 28.97% in the prior quarter.
• The five-year high for EBITDA Margin was 45.99% in Q4 2022, with the low at 9.63% in Q4 2025.
• Average EBITDA Margin over 5 years is 27.55%, with a median of 27.67% recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin soared 1783 bps in 2022, then tumbled 1860 bps in 2023.
• Over 5 years, EBITDA Margin stood at 45.99% in 2022, then sank by 40 bps to 27.38% in 2023, then retreated by 18 bps to 22.56% in 2024, then slumped by 57 bps to 9.63% in 2025, then soared by 206 bps to 29.48% in 2026.
• The last three EBITDA Margin figures came in at 29.48% (Q2 2026), 28.97% (Q1 2026), and 9.63% (Q4 2025), per Business Quant data.